Cargando…
Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2
BACKGROUND: JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated. Here, we aim to determine the effect and underlying mechanism of JAK1/2 inhibition on liver fibrosis and hepatic stellate cells (HSCs)...
Autores principales: | Song, Zhenghui, Liu, Xinhui, Zhang, Wan, Luo, Yue, Xiao, Hua, Liu, Yun, Dai, Guanqi, Hong, Jian, Li, Aimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981941/ https://www.ncbi.nlm.nih.gov/pubmed/35382859 http://dx.doi.org/10.1186/s12967-022-03366-y |
Ejemplares similares
-
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020) -
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib
por: Aboul-Fettouh, Nader, et al.
Publicado: (2018) -
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023) -
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023) -
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020)